There were decreases in live coefficients in the group with sPD-1 injection alone and the group with combination treatment, which was consistent with the report that liver immune-related adverse events are frequently observed in cancer patients treated with immune checkpoint inhibitors due to necrotic hepatocytes [44]. This evidence concerns the gene HOXD13 and cancer.